RAF709 10 mg | 99.43%
TargetMol
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
More Information Supplier PageRAF709
Search Results
RAF709 100 mg | 99.43%
TargetMol
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
More Information Supplier PageRAF709
GNE-3511 5 mg | 98.64%
TargetMol
GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.
More Information Supplier PageGNE-3511
GNE-3511 50 mg | 98.64%
TargetMol
GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.
More Information Supplier PageGNE-3511
GNE-3511 10 mg | 98.64%
TargetMol
GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.
More Information Supplier PageGNE-3511
GNE-3511 100 mg | 98.64%
TargetMol
GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.
More Information Supplier PageGNE-3511
Sotagliflozin 2 mg | 98.00%
TargetMol
LX-4211 is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.
More Information Supplier PageSotagliflozin
Sotagliflozin 25 mg | 98.00%
TargetMol
LX-4211 is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.
More Information Supplier PageSotagliflozin
Sotagliflozin 10 mg | 98.00%
TargetMol
LX-4211 is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.
More Information Supplier PageSotagliflozin
RG13022 5 mg | 98.38%
TargetMol
RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).
More Information Supplier PageRG13022
